Standaardisering van MET-amplificatietesten: beperkingen van het GCN≥6-criterium

We read with great interest the phase 2 KUNPENG trial by Yi-Long Wu and colleagues.1 The reported objective response rate of 48·8% with vebreltinib in MET amplification-driven non-small-cell lung cancer is promising. However, the use of a gene copy number (GCN) of six or higher as the sole enrolment criterion obscures crucial biological heterogeneity within this population. This methodological choice fundamentally limits the interpretability of the efficacy signal and poses a considerable risk for the design of the planned phase 3 trial.